AUTHOR INDEX

(P = Proceedings)

ABEL, S., NICHOLS, D.J., BREARLEY, C.J. & EVE, M.D. Effect of cimetidine and ranitidine on pharmcokinetics and pharmacodynamics of a single dose of dofetilide, 64
ABRAHAM, B.K., ADITHAN, C., SHASHINDRAN, C.H., VASU, S. & ALEKUTTY, N.A. Genetic polymorphism of CYP2D6 in a Keralite (South India) population, 285
ADITHAN, C. *see* ABRAHAM, B.K.
AGNEW, J.R. *see* THOMPSON, G.A.
AJJAN, R.A. *see* HUSSAIN, F.N.
ALEKUTTY, N.A. *see* ABRAHAM, B.K.
ALLICAR, M.P. *see* FOURRIER, A.
ANDERSEN, M. *see* LARSEN, J.
ANDREWS, J.A. *see* MCLAUGHLIN, D.B.
ANGUS, B.J., SMITH, M.D., SUPUTTAMONGKOL, Y., MATTIE, H., WALSH, A.L., WUTHIEKANUN, V., CHAOWAGUL, W. & WHITE, N.J. Pharmacokinetic-pharmacodynamic evaluation of ceftazidime continuous infusion *vs* intermittent bolus injection in septicaemic melioidosis, 445

BABER, N. & STONIER, P. Clinical pharmacology and the Faculty of Pharmaceutical Medicine, 523
BAILLIE, T.A. *see* PRUEKSARITANONT, T.
BAKER, E.H. Ion channels and the control of blood pressure, 185
BANKEN, L. *see* JORGA, K.
BARNETT, D.B. *see* SQUIRE, I.B.
BARON, J. *see* SORENSEN, H.T.
BARRETT, P.H.R. *see* DAVIS, T.M.E.
BASSENDINE, M.F. *see* WELFARE, M.R.
BAUER, P. *see* STACHER, G.
BéGAUD, B. *see* FOURRIER, A.
BEGAUD, B. *see* PIERFITTE, C.
BEGG, E.J., ROBSON, R.A., SAUNDERS, D.A., GRAHAM, G.G., BUTTIMORE, R.C., NEILL, A.M. & TOWN, G.I. The pharmacokinetics of oral fleroxacin and ciprofloxacin in plasma and sputum during acute and chronic dosing, 32
BEIJNEN, J.H. *see* KERBUSCH, T.
BEILBY, J.P. *see* DAVIS, T.M.E.
BEISE, R. *see* GROWCOTT, J.W.
BELCHER, G. *see* WATSON, H.R.
BERGMAN, U. *see* LARSEN, J.
BHARGAVA, P. *see* WILLIAMS, M.L.
BIRKETT, D.J. *see* MCLURE, J.A.
BIRNBOCK, H. *see* WITTKE, B.
BOUHASSIRA, M. *see* FOURRIER, A.
BOYCE, M. *see* CURTIS, S.P.
BRAUNSCHWEIG, S. *see* FATTINGER, K.
BREARLEY, C.J. *see* ABEL, S.
BREDDIN, H.K. *see* KLINKHARDT, U.
BRENNEISEN, R. *see* DE LA TORRE, R.
BRILEY, M. *see* HINDMARCH, I.
BRIQUE, S.A. *see* LIBERSA, C.C.
BROCKIS, J. *see* ILETT, K.F.
BROUWERS, J.R.B.J. *see* FIJN, R.
BUTTIMORE, R.C. *see* BEGG, E.J.

CALVO, R. *see* SUAREZ, E.
CAMÍ, J. *see* DE LA TORRE, R.
CANNELL, G.R. *see* MCLAUGHLIN, D.B.
CARLEBORG, L. *see* HÄGG, S.
CARON, J.F. *see* LIBERSA, C.C.
CASPI, A. *see* GREENBAUM, R.
CHAOWAGUL, W. *see* ANGUS, B.J.
CHERROUK, I. *see* WILLIAMS, M.L.
CHOONARA, I. *see* CONROY, S.
CHRISTENSEN, K. *see* SORENSEN, H.T.
CHRYSTYN, H. Methods to determine lung ditribution of inhaled drugs – could gamma scintigraphy be the gold standard, 525
CHUNG, J. *see* WITTKE, B.
CLEMENT, R.P. *see* GLUE, P.
CONROY, S., MCINTYRE, J., CHOONARA, I. & STEPHENSON, T. Drug trials in children: problems and the way forward, 93
COREY, A.E. *see* THOMPSON, G.A.
CURROW, D. *see* STUART-HARRIS, R.
CURTIS, S.P., EARDLEY, I., BOYCE, M., LARSON, P., HAESEN, R., GOTTESDIENER, K. & GERTZ, B.J. Single dose methodology to assess the influence of an α_1-adrenergic antagonist on uroflowmetric parameters in patients with benign prostatic hyperplasia, 269

DAHLQVIST, R. *see* HÄGG, S.
DALLOW, N. *see* WARD, J.K.
DALY, A.K. *see* WELFARE, M.R.
DALY, F. *see* DAVIS, T.M.E.
DAVIS, T.M.E., DALY, F., WALSH, J.P., ILETT, K.F., BEILBY, J.P., DUSCI, L.J. & BARRETT, P.H.R. Pharmacokinetics and pharmacodynamics of gliclazide in Caucasians and Australian Aborigines with type 2 diabetes, 223
DE ABAJO, F.J. & GARCIA RODRIGUEZ, L.A. Reply, 380
DE BOER, A. *see* LAU, H.S.
DE JONG-VAN DEN BERG, L.T.W. *see* FIJN, R.
DE LA TORRE, R., FARRÉ, M., ORTUÑO, J., MAS, M., BRENNEISEN, R., ROSET, P.N., SEGURA, J. & CAMÍ, J. Non-linear pharmacokinetics of MDMA ('ecstasy') in humans, 104
DEMEY, C. *see* GROWCOTT, J.W.
DENNIS, J. *see* FREEMANTLE, N.
DESTA, Z. *see* KO, J.W.
DEVOS, P. *see* LIBERSA, C.C.
DICKINSON, R.G. *see* MCLAUGHLIN, D.B.
DOW, J. *see* WARD, J.K.
DUSCI, L.J. *see* DAVIS, T.M.E.

EADIE, M.J. *see* MCLAUGHLIN, D.B.
EARDLEY, I. *see* CURTIS, S.P.
EDWARDS, G. *see* RAWDEN, H.C.
EICHELBAUM, M. *see* GROSS, A.S.
EKBOM, A. *see* SORENSEN, H.T.
ELAND, I.A., HUERTA ALVAREZ, C., STRICKER, B.H.CH. & GARCÍA RODRÍGUEZ, L.A. The risk of acute pancreatitis associated with acid-suppressing drugs, 473
ENGELS, S.A.G. *see* FIJN, R.
ENSOR, H. *see* WITTKE, B.
ERTEL, S.I. *see* WITTKE, B.
ESSLINGER, H.U. *see* KLINKHARDT, U.
EUROMAP, J. *see* SORENSEN, H.T.
EUSEBIO, R.A. *see* MITCHELL, D.Y.
EVE, M.D. *see* ABEL, S.
EYNOTT, P. *see* WARD, J.K.

FARMER, R.D.T. *see* LAWRENSON, R.
FARMER, R.D.T., LAWRENSON, R.A., TODD, J.-C., WILLIAMS, T.J., MACRAE, K.D., TYRER, F. & LEYDON, G.M. A comparison of the risks of venous thromboembolic disease in association with different combined oral contraceptives, 580
FARRÉ, M. *see* DE LA TORRE, R.
FATTINGER, K., ROOS, M., VERGÈRES, P., HOLENSTEIN, C., KIND, B., MASCHE, U., STOCKER, D.N., BRAUNSCHWEIG, S., KULLAK-UBLICK, G.A., GALEAZZI, R.L., FOLLATH, F., GASSER, T. & MEIER, P.J. Epidemiology of drug exposure and adverse drug reactions in two Swiss departments of internal medicine, 158
FAWCETT,. *see* ZHANG, M.
FEELY, J. *see* WILLIAMS, D.

© 2000 Blackwell Science Ltd

AUTHOR INDEX

(P = Proceedings)

ABEL, S., NICHOLS, D.J., BREARLEY, C.J. & EVE, M.D. Effect of cimetidine and ranitidine on pharmcokinetics and pharmacodynamics of a single dose of dofetilide, 64
ABRAHAM, B.K., ADITHAN, C., SHASHINDRAN, C.H., VASU, S. & ALEKUTTY, N.A. Genetic polymorphism of CYP2D6 in a Keralite (South India) population, 285
ADITHAN, C. *see* ABRAHAM, B.K.
AGNEW, J.R. *see* THOMPSON, G.A.
AJJAN, R.A. *see* HUSSAIN, F.N.
ALEKUTTY, N.A. *see* ABRAHAM, B.K.
ALLICAR, M.P. *see* FOURRIER, A.
ANDERSEN, M. *see* LARSEN, J.
ANDREWS, J.A. *see* MCLAUGHLIN, D.B.
ANGUS, B.J., SMITH, M.D., SUPUTTAMONGKOL, Y., MATTIE, H., WALSH, A.L., WUTHIEKANUN, V., CHAOWAGUL, W. & WHITE, N.J. Pharmacokinetic-pharmacodynamic evaluation of ceftazidime continuous infusion *vs* intermittent bolus injection in septicaemic melioidosis, 445

BABER, N. & STONIER, P. Clinical pharmacology and the Faculty of Pharmaceutical Medicine, 523
BAILLIE, T.A. *see* PRUEKSARITANONT, T.
BAKER, E.H. Ion channels and the control of blood pressure, 185
BANKEN, L. *see* JORGA, K.
BARNETT, D.B. *see* SQUIRE, I.B.
BARON, J. *see* SORENSEN, H.T.
BARRETT, P.H.R. *see* DAVIS, T.M.E.
BASSENDINE, M.F. *see* WELFARE, M.R.
BAUER, P. *see* STACHER, G.
BéGAUD, B. *see* FOURRIER, A.
BEGAUD, B. *see* PIERFITTE, C.
BEGG, E.J., ROBSON, R.A., SAUNDERS, D.A., GRAHAM, G.G., BUTTIMORE, R.C., NEILL, A.M. & TOWN, G.I. The pharmacokinetics of oral fleroxacin and ciprofloxacin in plasma and sputum during acute and chronic dosing, 32
BEIJNEN, J.H. *see* KERBUSCH, T.
BEILBY, J.P. *see* DAVIS, T.M.E.
BEISE, R. *see* GROWCOTT, J.W.
BELCHER, G. *see* WATSON, H.R.
BERGMAN, U. *see* LARSEN, J.
BHARGAVA, P. *see* WILLIAMS, M.L.
BIRKETT, D.J. *see* MCLURE, J.A.
BIRNBOCK, H. *see* WITTKE, B.
BOUHASSIRA, M. *see* FOURRIER, A.
BOYCE, M. *see* CURTIS, S.P.
BRAUNSCHWEIG, S. *see* FATTINGER, K.
BREARLEY, C.J. *see* ABEL, S.
BREDDIN, H.K. *see* KLINKHARDT, U.
BRENNEISEN, R. *see* DE LA TORRE, R.
BRILEY, M. *see* HINDMARCH, I.
BRIQUE, S.A. *see* LIBERSA, C.C.
BROCKIS, J. *see* ILETT, K.F.
BROUWERS, J.R.B.J. *see* FIJN, R.
BUTTIMORE, R.C. *see* BEGG, E.J.

CALVO, R. *see* SUAREZ, E.
CAMÍ, J. *see* DE LA TORRE, R.
CANNELL, G.R. *see* MCLAUGHLIN, D.B.
CARLEBORG, L. *see* HÄGG, S.
CARON, J.F. *see* LIBERSA, C.C.
CASPI, A. *see* GREENBAUM, R.
CHAOWAGUL, W. *see* ANGUS, B.J.
CHERROUK, I. *see* WILLIAMS, M.L.
CHOONARA, I. *see* CONROY, S.
CHRISTENSEN, K. *see* SORENSEN, H.T.
CHRYSTYN, H. Methods to determine lung ditribution of inhaled drugs – could gamma scintigraphy be the gold standard, 525
CHUNG, J. *see* WITTKE, B.
CLEMENT, R.P. *see* GLUE, P.
CONROY, S., MCINTYRE, J., CHOONARA, I. & STEPHENSON, T. Drug trials in children: problems and the way forward, 93
COREY, A.E. *see* THOMPSON, G.A.
CURROW, D. *see* STUART-HARRIS, R.
CURTIS, S.P., EARDLEY, I., BOYCE, M., LARSON, P., HAESEN, R., GOTTESDIENER, K. & GERTZ, B.J. Single dose methodology to assess the influence of an α_1-adrenergic antagonist on uroflowmetric parameters in patients with benign prostatic hyperplasia, 269

DAHLQVIST, R. *see* HÄGG, S.
DALLOW, N. *see* WARD, J.K.
DALY, A.K. *see* WELFARE, M.R.
DALY, F. *see* DAVIS, T.M.E.
DAVIS, T.M.E., DALY, F., WALSH, J.P., ILETT, K.F., BEILBY, J.P., DUSCI, L.J. & BARRETT, P.H.R. Pharmacokinetics and pharmacodynamics of gliclazide in Caucasians and Australian Aborigines with type 2 diabetes, 223
DE ABAJO, F.J. & GARCIA RODRIGUEZ, L.A. Reply, 380
DE BOER, A. *see* LAU, H.S.
DE JONG-VAN DEN BERG, L.T.W. *see* FIJN, R.
DE LA TORRE, R., FARRÉ, M., ORTUÑO, J., MAS, M., BRENNEISEN, R., ROSET, P.N., SEGURA, J. & CAMÍ, J. Non-linear pharmacokinetics of MDMA ('ecstasy') in humans, 104
DEMEY, C. *see* GROWCOTT, J.W.
DENNIS, J. *see* FREEMANTLE, N.
DESTA, Z. *see* KO, J.W.
DEVOS, P. *see* LIBERSA, C.C.
DICKINSON, R.G. *see* MCLAUGHLIN, D.B.
DOW, J. *see* WARD, J.K.
DUSCI, L.J. *see* DAVIS, T.M.E.

EADIE, M.J. *see* MCLAUGHLIN, D.B.
EARDLEY, I. *see* CURTIS, S.P.
EDWARDS, G. *see* RAWDEN, H.C.
EICHELBAUM, M. *see* GROSS, A.S.
EKBOM, A. *see* SORENSEN, H.T.
ELAND, I.A., HUERTA ALVAREZ, C., STRICKER, B.H.CH. & GARCÍA RODRÍGUEZ, L.A. The risk of acute pancreatitis associated with acid-suppressing drugs, 473
ENGELS, S.A.G. *see* FIJN, R.
ENSOR, H. *see* WITTKE, B.
ERTEL, S.I. *see* WITTKE, B.
ESSLINGER, H.U. *see* KLINKHARDT, U.
EUROMAP, J. *see* SORENSEN, H.T.
EUSEBIO, R.A. *see* MITCHELL, D.Y.
EVE, M.D. *see* ABEL, S.
EYNOTT, P. *see* WARD, J.K.

FARMER, R.D.T. *see* LAWRENSON, R.
FARMER, R.D.T., LAWRENSON, R.A., TODD, J.-C., WILLIAMS, T.J., MACRAE, K.D., TYRER, F. & LEYDON, G.M. A comparison of the risks of venous thromboembolic disease in association with different combined oral contraceptives, 580
FARRÉ, M. *see* DE LA TORRE, R.
FATTINGER, K., ROOS, M., VERGÈRES, P., HOLENSTEIN, C., KIND, B., MASCHE, U., STOCKER, D.N., BRAUNSCHWEIG, S., KULLAK-UBLICK, G.A., GALEAZZI, R.L., FOLLATH, F., GASSER, T. & MEIER, P.J. Epidemiology of drug exposure and adverse drug reactions in two Swiss departments of internal medicine, 158
FAWCETT,. *see* ZHANG, M.
FEELY, J. *see* WILLIAMS, D.

© 2000 Blackwell Science Ltd

FIJN, R., ENGELS, S.A.G., BROUWERS, J.R.B.J., KNAAP, R.J. & DE JONG-VAN DEN BERG, L.T.W. Dutch Hospital Drug Formularies: pharmacotherapeutic variation and conservatism, but concurrence with national pharmacotherapeutic guidelines, 254
FLOCKHART, D.A. *see* KO, J.W.
FLOCKHART, D.A. *see* WILLIAMS, M.L.
FLORAX, C. *see* LAU, H.S.
FOGARI, R. *see* LUSARDI, P.
FOLLATH, F. *see* FATTINGER, K.
FOTTELER, B. *see* JORGA, K.
FOURRIER, A., GASQUET, I., ALLICAR, M.P., BOUHASSIRA, M., LÉPINE, J.P. & BÉGAUD, B. Patterns of neuroleptic drug prescription: a national cross-sectional survey of a random samply of French psychiatrists, 80
FREEMANTLE, N., JOHNSON, R., DENNIS, J., KENNEDY, A. & MARCHMENT, M. Sleeping with the enemy? A randomized controlled trial of a collaborative health authority/industry intervention to influence prescribing practice, 174

GABRIELSSON, J. *see* NORBERG, Å.
GALEAZZI, R.L. *see* FATTINGER, K.
GARCIA RODRIGUEZ, L.A. *see* DE ABAJO, F.J.
GARCÍA RODRÍGUEZ, L.A. *see* ELAND, I.A.
GARRATT, C. *see* WESNES, K.A.
GASQUET, I. *see* FOURRIER, A.
GASSER, T. *see* FATTINGER, K.
GERTZ, B.J. *see* CURTIS, S.P.
GLUE, P., SCHENKER, S., GUPTA, S., CLEMENT, R.P., ZAMBAS, D. & SALFI, M. The single dose pharmacokinetics of ribavirin in subjects with chronic liver disease, 417
GOLLEDGE, C.L. *see* ILETT, K.F.
GOTTESDIENER, K. *see* CURTIS, S.P.
GRAHAM, G.G. *see* BEGG, E.J.
GRAHN, A.Y. *see* RABELINK, T.J.
GRANBERG, K. *see* HÄGG, S.
GREENBAUM, R., ZUCCHELLI, P., CASPI, A., NOURIEL, H., PAZ, R., SCLAROVSKY, S., O'GRADY, P., YEE, K.-F., LIAO, W.-C. & MANGOLD, B. Comparison of the pharmacokinetics of fosionprilat with enalaprilat and lisinopril in patients with congestive heart failure and chronic renal insufficieny, 23
GREENHILL, G. *see* ILETT, K.F.
GROSS, A.S., EICHELBAUM, M., MÖRIKE, K. & MIKUS, G. Pharmacokinetics and pharmacodynamics of R- and S-gallopamil during multiple dosing, 132
GROWCOTT, J.W., STONE, A., BEISE, R., STAMMER, H., TETZLOFF, W. & DEMEY, C. Sensitivity of repeated interdigital web pinching to detect antinociceptive effects of ibuprofen, 331
GUDGEON, A. *see* WESNES, K.A.
GUÉDON-MOREAU, L.M. *see* LIBERSA, C.C.
GUPTA, S. *see* GLUE, P.

HAAS, S. *see* KLINKHARDT, U.
HAEFELI, W.E. *see* HOTZ, M.A.
HAESEN, R. *see* CURTIS, S.P.
HÄGG, S., GRANBERG, K. & CARLEBORG, L. Excretion of fluvoxamine into breast milk, 287
HÄGG, S., SPIGSET, O., MJÖRNDAL, T. & DAHLQVIST, R. Effect of caffeine on clozapine pharmacokinetics in healthy volunteers, 59
HAHN, R.G. *see* NORBERG, Å.
HANSFORD, D. *see* KRSKA, J.
HARDER, S. *see* KLINKHARDT, U.
HIGUCHI, S. *see* TAKANAGA, H.
HILL, R.G. *see* LONGMORE, J.
HINDMARCH, I., RIGNEY, U., STANLEY, N. & BRILEY, M. Pharmacodynamics of milnacipran in young and elderly volunteers, 118
HOLENSTEIN, C. *see* FATTINGER, K.
HOLZAPFEL, A. *see* STACHER, G.
HOMBHANJE, F.W. Effect of a single oral dose of Fansidar™ on the pharmacokinetics of halofantrine in healthy volunteers: a preliminary report, 283
HONING, M.L.H. *see* RABELINK, T.J.
HOOPER, W.D. *see* MCLAUGHLIN, D.B.
HOTZ, M.A., RITZ, R., LINDER, L., SCOLLO-LAVIZZARI, G. & HAEFELI, W.E. Auditory and electroencephalographic effects of midazolam and α-hydroxy-midazolam in healthy subjects, 72
HUANG, S.-L. *see* OU-YANG, D.-S.
HUBER, K. *see* STACHER, G.
HUERTA ALVAREZ, C. *see* ELAND, I.A.
HUITEMA, A.D.R. *see* KERBUSCH, T.
HUMBERT, L. *see* LIBERSA, C.C.
HUSSAIN, F.N., AJJAN, R.A. & RILEY, S.A. Dose loading with delayed-release mesalazine: a study of tissue drug concentrations and standard pharmacokinetic parameters, 323
HUUPPONEN, R. *see* KALLIO, J.

ILETT, K.F. *see* DAVIS, T.M.E.
ILETT, K.F., JOHNSON, S., GREENHILL, G., MULLEN, L., BROCKIS, J., GOLLEDGE, C.L. & REID, D.B. Modification of general practitioner prescribing of antibiotics by use of a therapeutics adviser (academic detailer), 168

JICK, H. *see* MYERS, M.W.
JOEL, S.P. *see* STUART-HARRIS, R.
JOHN, D.N. *see* KRSKA, J.
JOHNSON, R. *see* FREEMANTLE, N.
JOHNSON, S. *see* ILETT, K.F.
JONES, A.W. *see* NORBERG, Å.
JORGA, K., FOTTELER, B., BANKEN, L., SNELL, P. & STEIMER, J.-L. Population pharmacokinetics of tolcapone in parkinsonian patients in dose finding studies, 39

KALATZIS, A. *see* KLINKHARDT, U.
KALLIO, J., SOMER, M., PESONEN, U., PYYKKO, K., HUUPPONEN, R. & SCHEININ, M. Influence of hydroxychloroquine or the bioavailability of oral metoprolol, 549
KAMBERI, M., NAKASHIMA, H., OGAWA, K., ODA, N. & NAKANO, S. The effect of staggered dosing of sucralfate on oral bioavailability of sparfloxacin, 98
KARBWANG, J. *see* TANARIYA, P.
KAUFMAN, M.R. *see* MYERS, M.W.
KEIZER, H.J. *see* KERBUSCH, T.
KELLY, A. *see* WILLIAMS, D.
KELLY, S.C. *see* MITCHELL, D.Y.
KENNEDY, A. *see* FREEMANTLE, N.
KENNEDY, E.J. *see* KRSKA, J.
KENNEDY, J.M. *see* ZHANG, M.
KENNEDY, J.M., VAN RIJ, A.M., SPEARS, G.F., PETTIGREW, R.A. & TUCKER, I.G. Polypharmacy in a general surgical unit and consequences of drug withdrawal, 353
KERBUSCH, T., HUITEMA, A.D.R., OUWERKERK, J., KEIZER, H.J., MATHT, R.A.A., SCHELLENS, J.H.M. & BEIJNEN, J.H. Evaluation of the autoinduction of ifosfamide metabolism by a population pharmacokinetic approach using NONMEM, 555
KIND, B. *see* FATTINGER, K.
KIVISTO, K.T. *see* LAPATTO-REINILUOTO, O.
KLINKHARDT, U., BREDDIN, H.K., ESSLINGER, H.U., HAAS, S., KALATZIS, A. & HARDER, S. Interaction between the LMWH reviparin and aspirin in healthy volunteers, 337
KNAAP, R.J. *see* FIJN, R.
KO, J.W., DESTA, Z., SOUKHOVA, N.V., TRACY, T. & FLOCKHART, D.A. *In vitro* inhibition of the cytochrome P450 (CYP450) system by the antiplatelet drug ticlopidine: potent effect on CYP2C19 and CYP2D6, 343

KOKWARO, G.O. *see* RAWDEN, H.C.
KRAUSE, G. *see* STACHER, G.
KRSKA, J., JOHN, D.N., HANSFORD, D. & KENNEDY, E.J. Drug utilization evaluation of non-prescription H_2-antagonists and alginate-containing preparations for dyspepsia, 363
KULLAK-UBLICK, G.A. *see* FATTINGER, K.
KURODA, K. *see* TAKANAGA, H.

LAPATTO-REINILUOTO, O., KIVISTO, K.T. & NEUVONEN, P.J. Gastric decontamination performed five min after the ingestion of temazepam, verapamil and moclobemide: charcoal is superior to lavage, 274
LARSEN, J., VACCHERI, A., ANDERSEN, M., MONTANARO, N. & BERGMAN, U. Lack of adherence to lipid-lowering drug treatment. A comparison of utilization patterns in defined populations in Funen, Denmark and Bologna, Italy, 463
LARSON, P. *see* CURTIS, S.P.
LARSSON, P. *see* Rosenborg, J.
LAU, H.S., FLORAX, C., PORSIUS, A.J. & DE BOER, A. The completeness of medication histories in hospital medical records of patients admitted to general internal medicine wards, 597
LAUSECKER, B. *see* WITTKE, B.
LAWRENSON, R., TODD, J.-C., WILLIAMS, T.J. & FARMER, R.D.T. Validation of the diagnosis of venous thromboembolism in general practice database studies, 591
LAWRENSON, R.A. *see* FARMER, R.D.T.
LÉPINE, J.P. *see* FOURRIER, A.
LEYDON, G.M. *see* FARMER, R.D.T.
LHERMITTE, M.A. *see* LIBERSA, C.C.
LIAO, W.-C. *see* GREENBAUM, R.
LIBERSA, C.C., BRIQUE, S.A., MOTTE, K.B., CARON, J.F., GUÉDON-MOREAU, L.M., HUMBERT, L., VINCENT, A., DEVOS, P. & LHERMITTE, M.A. Dramatic inhibition of amiodarone metabolism induced by grapefruit juice, 373
LIN, J.H. *see* PRUEKSARITANONT, T.
LINDER, L. *see* HOTZ, M.A.
LIPPERT, T.H., MUECK, A.O. & SEEGER, H. Is the use of conjugated equine oestrogens in hormone replacement therapy still appropriate?, 489
LONGMORE, J., MAGUIRE, J.J., MACLEOD, A., STREET, L., SCHOFIELD, W.N. & HILL, R.G. Comparison of the vasoconstrictor effects of the selective 5-HT_{1D}-receptor agonist L-775,606 with the mixed 5-$HT_{1B/1D}$-receptor agonist sumatriptan and 5-HT in human isolated coronary artery, 126
LUKAS, J. *see* SUAREZ, E.
LUSARDI, P., PIAZZA, E. & FOGARI, R. Cardiovascular effects of melatonin in hypertensive patients well controlled by nifedipine: a 24-hour study, 423

MACHIN, S.J. *see* WITTKE, B.
MACKIE, I.J. *see* WITTKE, B.
MACLEOD, A. *see* LONGMORE, J.
MACRAE, K.D. *see* FARMER, R.D.T.
MAGUIRE, J.J. *see* LONGMORE, J.
MANGOLD, B. *see* GREENBAUM, R.
MARCHMENT, M. *see* FREEMANTLE, N.
MARSHALL, J.L. *see* WILLIAMS, M.L.
MAS, M. *see* DE LA TORRE, R.
MASCHE, U. *see* FATTINGER, K.
MATHT, R.A.A. *see* KERBUSCH, T.
MATSUO, H. *see* TAKANAGA, H.
MATTIE, H. *see* ANGUS, B.J.
MAZOIT, J.X. & SAMII, K. Reply, 382
MCCLEANE, G.J. Topical application of doxepin hydrochloride, capsaicin and a combination of both in chronic human neuropathic pain: a randomized, double-blind, placebo-controlled study, 574
MCDONALD, P. *see* STUART-HARRIS, R.
MCINTYRE, J. *see* CONROY, S.
MCLAUGHLIN, D.B., ANDREWS, J.A., HOOPER, W.D., CANNELL, G.R., EADIE, M.J. & DICKINSON, R.G. Apparent autoinduction of valproate β-oxidation in humans, 409
MCLURE, J.A., MINERS, J.O. & BIRKETT, D.J. Nonspecific binding of drugs to human liver microsomes, 453
MEIER, P.J. *see* FATTINGER, K.
MIKUS, G. *see* GROSS, A.S.
MILLERI, S. *see* WARD, J.K.
MINERS, J.O. *see* MCLURE, J.A.
MITCHELL, D.Y., ST PETER, J.V., EUSEBIO, R.A., PALLONE, K.A., KELLY, S.C., RUSSELL, D.A., NESBITT, J.D., THOMPSON, G.A. & POWELL, J.H. Effect of renal function on risedronate pharmacokinetics after a single oral dose, 215
MITCHELL, P.B. Therapeutic drug monitoring of psychotropic medications, 303
MJöRNDAL, T. *see* HÄGG, S.
MONTANARO, N. *see* LARSEN, J.
MOORE, N. *see* PIERFITTE, C.
MöRIKE, K. *see* GROSS, A.S.
MORRISON, P.J. *see* RABELINK, T.J.
MOTTE, K.B. *see* LIBERSA, C.C.
MüCK, W. Metabolic interactions between mibefradil and HMG-CoA reductase inhibitors: linking *in vitro* with *in vivo* information, 87
MUCKLOW, J.C. Martindale: The Complete Drug Reference, 613
MUECK, A.O. *see* LIPPERT, T.H.
MULLEN, L. *see* ILETT, K.F.
MURAKAMI, H. *see* TAKANAGA, H.
MYERS, M.W., VASILAKIS, C., KAUFMAN, M.R. & JICK, H. Antihypertensive drugs and the risk of idiopathic aplastic anaemia, 604

NA-BANGCHANG, K. *see* TANARIYA, P.
NAKAJIMA, M. *see* OHYAMA, K.
NAKANO, S. *see* KAMBERI, M.
NAKASHIMA, H. *see* KAMBERI, M.
NEILL, A.M. *see* BEGG, E.J.
NESBITT, J.D. *see* MITCHELL, D.Y.
NESBITT, J.D. *see* THOMPSON, G.A.
NEUVONEN, P.J. *see* LAPATTO-REINILUOTO, O.
NEWMAN, S.P. Can lung deposition data act as a surrogate for the clinical response to inhaled asthma drugs?, 529
NICHOLS, D.J. *see* ABEL, S.
NIELSEN, G.L. *see* SORENSEN, H.T.
NORBERG, Å., GABRIELSSON, J., JONES, A.W. & HAHN, R.G. Within- and between-subject variations in pharmacokinetic parameters of ethanol by analysis of breath, venous blood and urine, 399
NOURIEL, H. *see* GREENBAUM, R.
NYBERG, L. *see* ROSENBORG, J.

O'GRADY, P. *see* GREENBAUM, R.
ODA, N. *see* KAMBERI, M.
OGAWA, K. *see* KAMBERI, M.
OHNISHI, A. *see* TAKANAGA, H.
OHYAMA, K., NAKAJIMA, M., SUZUKI, M., SHIMADA, N., YAMASAKI, H. & YOKOI, T. Inhibitory effects of amiodarone and its *N*-deethylated metabolite on human cytochrome P450 activities: Prediction of *in vivo* drug interactions, 244
OLIVER, S. *see* WESNES, K.A.
ORTUÑO, J. *see* DE LA TORRE, R.
OUWERKERK, J. *see* KERBUSCH, T.
OU-YANG, D.-S., HUANG, S.-L., WANG, W., XIE, H.-G., XU, Z.-H. & ZHOU, H.-H. Phenotypic polymorphism and gender-related differences of CYP1A2 activity in a Chinese population, 145

PADLEY, R.J. *see* RABELINK, T.J.
PALLONE, K.A. *see* MITCHELL, D.Y.
PARIKH, C. Anti-depressants in the elderly: challenges for study design and their interpretation, 539
PAZ, R. *see* GREENBAUM, R.
PESONEN, U. *see* KALLIO, J.
PETTIGREW, R.A. *see* KENNEDY, J.M.

© 2000 Blackwell Science Ltd

PIAZZA, E. *see* LUSARDI, P.
PIERFITTE, C., ROYER, R.J., MOORE, N. & BEGAUD, B. The link between sunshine and phototoxicity of sparfloxacin, 609
PORSIUS, A.J. *see* LAU, H.S.
POWELL, J.H. *see* MITCHELL, D.Y.
POWELL, J.H. *see* THOMPSON, G.A.
PRESCOTT, L.F. Paracetamol, alcohol and the liver, 291
PRUEKSARITANONT, T., LIN, J.H. & BAILLIE, T.A. Reply, 90
PYYKKO, K. *see* KALLIO, J.

RABELINK, T.J., VERHAAR, M.C., GRAHN, A.Y., VAN WEERDT, A.W.M., HONING, M.L.H., MORRISON, P.J., YANG, Y.P. & PADLEY, R.J. Pharmacokinetics and pharmacodynamic effects of ABT-627, an oral ETA selective endothelin antagonist, in humans, 562
RAWDEN, H.C., KOKWARO, G.O., WARD, S.A. & EDWARDS, G. Relative contribution of cytochromes P-450 and flavin-containing monoxygenases to the metabolism of albendazole by human liver microsomes, 313
REID, D.B. *see* ILETT, K.F.
RIGNEY, U. *see* HINDMARCH, I.
RILEY, S.A. *see* HUSSAIN, F.N.
RITZ, R. *see* HOTZ, M.A.
ROBSON, R.A. *see* BEGG, E.J.
ROOS, M. *see* FATTINGER, K.
ROSENBORG, J., LARSSON, P. & NYBERG, L. Pharmacokinetics of bambuterol during oral administration of plain tablets and solution to healthy adults, 199
ROSET, P.N. *see* DE LA TORRE, R.
ROYER, R.J. *see* PIERFITTE, C.
RUSSELL, D.A. *see* MITCHELL, D.Y.

SALFI, M. *see* GLUE, P.
SAMII, K. *see* MAZOIT, J.X.
SATA, H. *see* TAKANAGA, H.
SAUNDERS, D.A. *see* BEGG, E.J.
SAWADA, Y. *see* TAKANAGA, H.
SCHEININ, M. *see* KALLIO, J.
SCHELLENS, J.H.M. *see* KERBUSCH, T.
SCHENKER, S. *see* GLUE, P.
SCHOFIELD, W.N. *see* LONGMORE, J.
SCLAROVSKY, S. *see* GREENBAUM, R.
SCOLLO-LAVIZZARI, G. *see* HOTZ, M.A.
SEEGER, H. *see* LIPPERT, T.H.
SEGURA, J. *see* DE LA TORRE, R.
SHASHINDRAN, C.H. *see* ABRAHAM, B.K.
SHAW, J.P. *see* ZHANG, M.
SHIMADA, N. *see* OHYAMA, K.
SKENE, A.M. *see* WATSON, H.R.
SLEVIN, M.L. *see* STUART-HARRIS, R.
SMITH, M.D. *see* ANGUS, B.J.
SNELL, P. *see* JORGA, K.
SOMER, M. *see* KALLIO, J.
SORENSEN, H.T., NIELSEN, G.L., CHRISTENSEN, K., TAGE-JENSEN, U., EKBOM, A., BARON, J., EUROMAP, J. & STUDY GROUP, J. Birth outcome following maternal use of metoclopramide, 264
SOUKHOVA, N.V. *see* KO, J.W.
SPEARS, G.F. *see* KENNEDY, J.M.
SPIGSET, O. *see* HÄGG, S.
SQUIRE, I.B & BARNETT, D.B. The rational use of β-adrenoceptor blockers in the treatment of heart failure. The changing face of an old therapy, 1
ST PETER, J.V. *see* MITCHELL, D.Y.
STACHER, G., WEBER, U., STACHER-JANOTTA, G., BAUER, P., HUBER, K., HOLZAPFEL, A., KRAUSE, G. & STEINBORN, C. Effects of the 5-HT_3 antagonist cilansetron *vs* placebo on phasic sigmoid colonic motility in healthy man: a double-blind crossover trial, 429
STACHER-JANOTTA, G. *see* STACHER, G.
STAMMER, H. *see* GROWCOTT, J.W.
STANLEY, N. *see* HINDMARCH, I.
STEIMER, J.-L. *see* JORGA, K.
STEINBORN, C. *see* STACHER, G.
STEPHENSON, T. *see* CONROY, S.
STOCKER, D.N. *see* FATTINGER, K.
STONE, A. *see* GROWCOTT, J.W.
STONIER, P. *see* BABER, N.
STREET, L. *see* LONGMORE, J.
STRICKER, B.H.CH. *see* ELAND, I.A.
STUART-HARRIS, R., JOEL, S.P., MCDONALD, P., CURROW, D. & SLEVIN, M.L. The pharmacokinetics of morphine and morphine glucuronide metabolites after subcutaneous bolus injection and subcutaneous infusion of morphine, 207
STUDY GROUP, J. *see* SORENSEN, H.T.
SUAREZ, E., CALVO, R., ZAMACONA, M.K. & LUKAS, J. Binding of propofol to blood components, 381
SUISSA, S. Ventricular arrhythmias and nonsedating antihistamines, 379
SUPUTTAMONGKOL, Y. *see* ANGUS, B.J.
SUZUKI, M. *see* OHYAMA, K.

TAGE-JENSEN, U. *see* SORENSEN, H.T.
TAKANAGA, H., OHNISHI, A., MATSUO, H., MURAKAMI, H., SATA, H., KURODA, K., URAE, A., HIGUCHI, S. & SAWADA, Y. Pharmacokinetic analysis of felodipine–grapefruit juice interaction based on an irreversible enzyme inhibition model, 49
TANARIYA, P., TIPPAWANGKOSO, P., KARBWANG, J., NA-BANGCHANG, K. & WERNSDORFER, W.H. *In vitro* sensitivity of *Plasmodium falciparum* and clinical response to lumefantrine (benflumetol) and artemether, 437
TASSANEEYAKUL, W. *see* TASSANEEYAKUL, W.
TASSANEEYAKUL, W., TASSANEEYAKUL, W., VANNAPRASAHT, S. & YAMAZOE, Y. Formation of omeprazole sulphone but not 5-hydroxyomeprazole is inhibited by grapefruit juice, 139
TETZLOFF, W. *see* GROWCOTT, J.W.
THOMAS, S.H.L. *see* YEATES, P.J.A.
THOMPSON, G.A. *see* MITCHELL, D.Y.
THOMPSON, G.A., COREY, A.E., AGNEW, J.R., VALENTINE, S.N., NESBITT, J.D., WAGNER, D.L. & POWELL, J.H. Comparative oral bioavailability of azimilide dihydrochloride in the fed and fasted states, 279
TIPPAWANGKOSO, P. *see* TANARIYA, P.
TODD, J.-C. *see* FARMER, R.D.T.
TODD, J.-C. *see* LAWRENSON, R.
TOWN, G.I. *see* BEGG, E.J.
TRACY, T. *see* KO, J.W.
TUCKER, I.G. *see* KENNEDY, J.M.
TYRER, F. *see* FARMER, R.D.T.

URAE, A. *see* TAKANAGA, H.

VACCHERI, A. *see* LARSEN, J.
VALENTINE, S.N. *see* THOMPSON, G.A.
VAN RIJ, A.M. *see* KENNEDY, J.M.
VAN WEERDT, A.W.M. *see* RABELINK, T.J.
VANNAPRASAHT, S. *see* TASSANEEYAKUL, W.
VASILAKIS, C. *see* MYERS, M.W.
VASU, S. *see* ABRAHAM, B.K.
VENTRESCA, G.P. *see* WARD, J.K.
VERGèRES, P. *see* FATTINGER, K.
VERHAAR, M.C. *see* RABELINK, T.J.
VINCENT, A. *see* LIBERSA, C.C.

WAGNER, D.L. *see* THOMPSON, G.A.
WAINER, I.W. *see* WILLIAMS, M.L.
WALSH, A.L. *see* ANGUS, B.J.
WALSH, J.P. *see* DAVIS, T.M.E.
WANG, W. *see* OU-YANG, D.-S.
WARD, J.K., DOW, J., DALLOW, N., EYNOTT, P., MILLERI, S. & VENTRESCA, G.P. Enantiomeric disposition of inhaled, intravenous and oral racemic-salbutamol in man — no evidence of enantioselective lung metabolism, 15
WARD, S.A. *see* RAWDEN, H.C.

WARING, W.S. & WEBB, D.J. Instant Pharmacology, 91
WATSON, H.R., SKENE, A.M. & BELCHER, G. Graft materials and results of platelet inhibitor trials in peripheral arterial reconstructions: reappraisal of results from a meta-analysis, 479
WEBB, D.J. *see* WARING, W.S.
WEBER, U. *see* STACHER, G.
WELFARE, M.R., BASSENDINE, M.F. & DALY, A.K. The effect of NAT2 genotype and gender on the metabolism of caffeine in non-smoking subjects, 240
WERNSDORFER, W.H. *see* TANARIYA, P.
WESNES, K.A., GARRATT, C., WICKENS, M., GUDGEON, A. & OLIVER, S. Effects of sibutramine alone and with alcohol on cognitive function in healthy volunteers, 110
WHITE, N.J. *see* ANGUS, B.J.
WICKENS, M. *see* WESNES, K.A.
WILLIAMS, D., KELLY, A. & FEELY, J. Drug interactions avoided – a useful indicator of good prescribing practice, 369
WILLIAMS, M.L., BHARGAVA, P., CHERROUK, I., MARSHALL, J.L., FLOCKHART, D.A. & WAINER, I.W. A discordance of the cytochrome P450 2C19 genotype and phenotype in patients with advanced cancer, 485
WILLIAMS, T.J. *see* FARMER, R.D.T.
WILLIAMS, T.J. *see* LAWRENSON, R.
WILSON, C.G. Encyclopaedia of Controlled Drug Delivery, 92
WITTKE, B., ENSOR, H., CHUNG, J., BIRNBOCK, H., LAUSECKER, B., ERTEL, S.I., MACKIE, I.J. & MACHIN, S.J. Pharmacokinetics and pharmacodynamics of sibrafiban alone or in combination with ticlopidine and aspirin, 231
WUTHIEKANUN, V. *see* ANGUS, B.J.
XIE, H.-G. *see* OU-YANG, D.-S.
XU, Z.-H. *see* OU-YANG, D.-S.

YAMASAKI, H. *see* OHYAMA, K.
YAMAZOE, Y. *see* TASSANEEYAKUL, W.
YANG, Y.P. *see* RABELINK, T.J.
YEATES, P.J.A. & THOMAS, S.H.L. Effectiveness of delayed activated charcoal administration in simulated paracetamol (acetaminophen) overdose, 11
YEE, K.-F. *see* GREENBAUM, R.
YOKOI, T. *see* OHYAMA, K.

ZAMACONA, M.K. *see* SUAREZ, E.
ZAMBAS, D. *see* GLUE, P.
ZHANG, M., FAWCETT, ?., KENNEDY, J.M. & SHAW, J.P. Stereoselective glucuronidation of formoterol by human liver microsomes, 152
ZHOU, H.-H. *see* OU-YANG, D.-S.
ZUCCHELLI, P. *see* GREENBAUM, R.

© 2000 Blackwell Science Ltd

SUBJECT INDEX

This index was compiled from the keywords
(P = Proceedings, S = Supplement)

α-hydroxy-midazolam, 72
α_1-adrenoceptor antagonist, 269
ABPM, 423
Absorption, 279
ABT-627, 562
Academic detailing, 168
ACE inhibitors, 254
Acenocoumarol, 391P
Acetylsalicylic acid, 337
Acid-suppressing drugs, 473
Acoustically evoked potentials, 72
Activated charcoal, 11
Acute lymphoblastic anaemia, 501P
Acute pancreatitis, 473
Advanced cancer patients, 485
Adverse drug events, 387P
Adverse drug reactions, 158
Age, 15S
Albendazole, 313
Alcohol, 110, 399
Alginates, 363
Aluminium, 57S
Alzheimer's disease, 503P
Amiodarone, 244, 373
Amitriptyline, 118, 515P
Amphetamine abuse, 508P
Angiotensin converting enzyme, 23
Angiotensin II inhibitors, 254
Angiotensin II, 396P
Anthelmintic, 313
Antiarrhythmic drug, 64
Antibiotics, 168, 494P
Antibody profile, 506P
Anticonvulsants, 409
Antidepressants, 118, 303, 383P, 539P
Antihypertensive drugs, 394P
Antiplatelet, 343
Antipsychotic drugs, 80, 492P
Antipsychotics, 303
Antitussives, 517P
Aplastic anaemia, 605
Artemether, 437
Artemisinin, 437
Arterial wave reflection, 510P
ASA-interaction, 337
5-ASA, 323
Aspirin, 231, 498P
Asthma, 516P, 529
ATC code, 254
Athletes, 388P
Attention, 110
Australian aborigines, 223
Autoimmunity, 506P
Autoinduction, 409, 555
Autonomic function, 515P
Azimilide, 279

β_1-adrenoceptor stimulation, 497P
β_2-adrenoceptor stimulation, 497P
β_3-adrenoceptors, 387P
β_4-adrenoceptor, 496P
β-adrenoceptor blockers, 1
β-adrenoceptor blocking agents, 254
β-oxidation, 409
Bambuterol, 199
Bartter's syndrome, 185
Benflumetol, 437
Benign prostatic hyperplasia, 269
Benzodiazepines, 254
Binding, 381
Bioavailability, 279, 390P, 395P, 502P
Bioequivalence, 199
Birth outcome, 264
Bleeding time, 337
Blood pressure, 185, 510P, 512P
Bone cancer, 385P
Breast milk, 286
Bromide, 394P
Bronchodilators, 529
Burkholderia pseudomallei, 445

Caffeine, 59, 145, 240
Calcium absortion, 386P
Calcium channel blockers, 254, 605
Capsaicin, 574
Carbamazepine, 65S, 385P, 500P, 519P
Cardiac repolarisation, 492P
Cardiovascular disease, 498P
Caucasians, 223
Ceftazidime, 445
Central nervous function, 514P
Charcoal, 274
Cholesterol lowering drug use, 384P
Cholinesterase inhibitor, 503P
Cilansetron, 429
Cimetidine, 57S, 64
Ciprofloxacin, 32
Citric acid induced cough, 517P
Clearance rate, 389P
Clinical pharmacology, 523
Clinical trials, 93
Clozapine, 59
Cognitive function, 110
Cognitive function, 118
Collagenase selective inhibitor, 502P
Colonic motility, 429
Compliance, 394P, 512P
Complication, 353
COMT inhibitor, 39
Congestive heart failure,23
Conjugated equine oestrogens, 489
Continuous infusion, 445
Contraceptive, 49S
Coronary heart disease, 513P
Coronary risk, 514P

Corticosteroids, 516P, 529
Cotrimoxazole, 518P
Cross-sectional study, 80
Cross-sectoral pharmacotherapy, 254
Cutaneous reactions, 520P
Cyclosporin A, 390P
CYP1A2, 59, 240
CYP2C19, 139, 485
CYP2C9, 391P, 503P
CYP2D6, 180, 285, 549
CYP2E1, 291
CYP3A4, 139, 504P
Cyproheptadine, 507P
Cytochrome P450, 35S, 145, 180, 244, 291, 313, 343, 390P, 503P

Database studies, 580, 592
Debrisoquine, 180
Depression, 383p
Desethylamiodarone, 244
Dexamethasone, 504P
Dextromethorphan, 43S, 549
Dextrophan, 43S
Diabetes, 512P
Diadenosine pentaphosphate, 392P
Diltiazem, 505P
Docetaxel, 390p
Dofetilide, 64
Dose-loading, 323
Double-blind cross-over trial, 529
Doxepin, 574
Drug deposition, 529
Drug expenditures, 254
Drug interaction, 59, 98, 110
Drug interactions, 35S
Drug response, 437
Drug therapy, 353
Drug utilization evaluation, 363
Drug utilization study, 80
Drug withdrawal, 353

Ecstasy, 104
[153Sm] EDTMP, 385P
Elderly volunteers, 118
Elderly, 539
Electroencephalogram, 72
Enalapril, 23
Enalaprilat, 23
Enantiomers, 15, 132
Endothelial function, 511P
Endothelin antagonist, 562
Endothelin-1 ET1-31, 510P
Endothelin-I, 495P
Endothelins, 562
Enzyme kinetics, 35S
Epidemiology, 473
Epithelium, 185
Erbium, 383P

© 2000 Blackwell Science Ltd

Essential drugs list, 254
Essential hypertension 396P
Ethanol, 291, 399
Ethinyloestradiol, 49S
Event monitoring, 158
Extrapyramidal symptoms, 5S

Fansidar, 283
Felodipine, 49
Flavin monoxygenases, 313
Fleroxacin, 32
Fluvoxamine, 286
Food effect, 279
Forearm blood flow, 511P
Formoterol, 152
Fosinopril, 223
Fosinoprilat, 23
France, 80

Gallopamil, 132
Ganstigmine, 503P
Gastric lavage, 274
Gastric pH, 493P
Gastrin antagonist, 493P
Gender, 15S
Gender-related differneces, 145
Gene amplification, 180
Gene duplication, 180
Gene expression, 500P
General internal ward, 598
General medical services, 369
General practitioners, 168
Genetic polymorphism, 285
Genotype, 180, 485
Glicazide, 223
Glucuronidation, 409
GPIIb/IIIa antagonist, 231
Graft material, 479
Grapefruit juice, 49, 139. 373

5-hydroxytryptamine$_3$ receptor antagonist, 429
5-HT receptor agonists, 126
5HT$_3$-antagonists, 254
H+-pump inhibitors, 254
H$_2$-receptor antagonists, 254. 363
Haemodialysis, 27S
Halofantrine, 283
Haptenation, 518P
Healthy volunteers, 72, 132
Heart failure, 1
Heart, human, 496P
[186Re] HEDP, 385P
Helicobacter pylori, 494P, 506P
Hepatic impairment, 21S
Hepatotoxicity, 291
HIV, 389P
HIV-positive patients, 499P
HMG-CoA reductase inhibitors, 87, 513P, 514P
Hormone replacement therapy, 489
Hospital, 598
Hospital drug formularies, 254
Hospital pharmacoepidemiology, 158
Hospital stay, 387P

Human coronary arteries, 126
Human liver microsomes, 35S, 152, 453
Human skin microcirculation, 510P
Human, 199, 562
Humans, 104
Hydroxocobalamin, 395P
Hydroxychloroquine, 549
Hypersensitivity reactions, 500P
Hypersensitivity, 518P, 519P
Hypertension, 394P, 512P
Hypertensives, 423
Hyperuricaemia, 511P

Ibuprofen, 331
ICPC-Ph subcode, 254
Ifosfamide, 390P, 555
99mTc-iminothiolane-Annexin V, 392P
In vitro clearance prediction, 453
In vitro drug metabolism, 453
Inactivation, 244
Individualized prescription databases, 463
Infusion, 207
Inhaled, 15
Inhibition, 244, 343
Inpatients, 158
Interaction, 49S, 57S, 65S, 71S, 139, 291, 373, 549
Interdigital web pinching, 331
International comparison, 463
Intestinal P450, 139
Intravenous, 15
Ion channels, 185
Ireland, 369
Isoenzymes, 291
Isoprenaline, 387P

Keral population, 285
Ketoconazole, 71S

L 753,037, 495P
Lamotrigine, 519P, 520P

Levonorgestrel, 49S
Licensed, 93
Liddle's syndrome, 185
Lipid lowering drug utilization, 463
Lipid utilization, 387P
Lisinopril, 23
Lithium, 61S, 303
Lithium, 61S
Liver disease, 417
Lumefantrine, 437
Lung function, 388P
Lymphocyte reactivity, 520P

Magnesium, 57S
MDMA, 104
Meal stimulation, 429
Medical records, 598
Medication histories, 598
Medication usage, 158
Medicines in children, 93
Melatonin, 423
Melioidosis therapy, 445
Meropenem, 393P

Mesalazine, 323
Meta-analysis, 479
Metabolism, 15,21S, 43S 313, 373
Metoclopramide, 264
Metoprolol, 549
Mibefradil, 87
Midazolam, 72
Milnacipram, 118
Modelling, 49
Morphine, 207
Morphine-3-glucuronide, 207
Morphine-6-glucuronide, 207
Myocardial infarction, 392P

NAT2, 240
Nelfinavir, 499P
Neostigmine, 429
Neuropathic pain, 574
Nevirapine, 389P
Nifedipine, 423, 598
Non-linear kinetics, 399
NONMEM, 555
Non-prescription products, 363
Non-sedating antihistamines, 379
Non-selective endothelin receptor antagonist, 495P
Nonspecific binding, 453
NSAIDs, 254

Odds ratio, 369
17B-oestradiol, 500P
Off-label, 93
Omeprazole, 139
Oral contraceptive, 514P, 580, 592
Oral, 15
Outreach visits, 174
Overdose, 291

Paediatric drug therapy, 93
Pain, 331
Paracetamol overdose, 11
Paracetamol, 291
Parkinsonism, 506P
Paroxetine, 43S
Peripheral bypass, 479
Persisitence, 463
Pharmaceutical industry/health authority collaboration, 174
Pharmaceutical medicine, 523
Pharmacodynamic effects, 503P
Pharmacodynamics, 64, 132, 223, 393P, 445
Pharmacoepidemiology, 80
Pharmacogenetics, 145
Pharmacokinetics, 5S15, 15S, 21S, 23, 27S, 32, 39, 43S, 49, 49S, 57S, 59, 61S, 64, 65S, 71S, 72, 104, 132, 199, 207, 215, 223, 279, 283, 323, 373, 385P, 390P, 392P, 393P, 399, 417, 445, 499P, 500P, 504P
Pharmacotherapeutic guidelines, 254
Pharmacovigilance, 473
Pharmacy records, 598
Phasic contractile activity, 429
Phenotype, 180, 485

© 2000 Blackwell Science Ltd

Phototoxicity, 610
Pill scare, 580
Piracetam, 491P
Pirenzipine, 497P
Plasma, 32
Plasmodium falciparum, 437
Platelet inhibitors, 479
Platelets, 231
Polymorphism, 145, 391P, 396P
Population pharmacokinetics, 555
Postmenopausal, 500P
Pregnancy, 264
Prescribing practice, 174
Prescribing, 168, 518P
Propofol, 381
Proton pump inhibitor, 139, 494P
Psychomotor performance, 118
Psychotropic, 303

QT dispersion, 509P
QT interval, 509P
QTC dispersion, 509P
QTC interval, 509P
Quality prescribing, 369
Quinidine, 180

Randomized evaluation, 174
Rac-salbutamol, 15
Radiation synovectomy, 383P
Ranitidine, 64, 493P
Renal clearance, 61S
Renal function, 215
Renal impairment, 27S, 215
Renal insufficiency, 23
Reviparin, 337
Ribavirin, 417
Risedronate, 215
Risk factors, 580

Salbutamol, 388P
Samarium, 383P
Schizoaffective, 15S
Schizophrenia, 15S, 491P, 507P
Secondary memory, 110
Serum prolactin, 5S
Sibrafiban, 231
Sibutramine, 110
Sildenafil, 510P
Simvastatin, 505P
Sparfloxacin, 98, 610
Sputum, 32
[89Sr] chloride, 385P
Stereoselective glucuronidation, 152
Stroke, 394P
Strontium, 386P
Subcutaneous, 207
Sucralfate, 98
Sulphamethoxazole, 518P
Sunshine, 610
Surgical patients, 353

Tamoxifen, 503P
Temazepam, 274
Terbutaline, 199
Theophylline, 392 P
Therapeutic drug monitoring, 303
Therapeutic misadventure, 291
Therapeutic use, 291
Therapeutic window, 383P
Therapeutics adviser, 168
Thermogenesis, 387P
Thiopurine methyltransferase, 501P
Ticlopidine, 231, 343
Tissue concentration, 323
Tolcapone, 39
Transiently evoked otoacoustic emissions, 72
Tricyclic antidepressants, 574
Trimethoprim, 518P
Trocade, 502P

Unlicensed, 93
Uroflowmetry, 269

Validity, 592
Valproate, 409
Variance components, 399
Vascular tone, 185
Vasoactive properties, 510P
Vasoconstriction, 126
Venous thromboembolism, 580, 592
Ventricular arrhythmias, 379
Verapamil, 274, 505P
Volunteers, 331

Working memory, 110

YF476, 493P
Yttrium, 383P

Ziprasidone, 5S, 15S, 21S, 27S, 35S, 43S, 49S, 57S, 61S, 65S, 71S